ASOs are an effective treatment for disease-associated oligodendrocyte signatures in premanifest and symptomatic SCA3 mice
Kristen H. Schuster(University of Michigan), Hayley S. McLoughlin(University of Michigan)
Cited by 2
Related Papers
Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice
|Annals of Neurology|2018|156
ASOs are an effective treatment for disease-associated oligodendrocyte signatures in premanifest and symptomatic SCA3 mice
|Molecular Therapy|2024|19
Disease-associated oligodendrocyte signatures are spatiotemporally dysregulated in spinocerebellar ataxia type 3
|Frontiers in Neuroscience|2023|16
Early transcriptomic perturbations highlight the spinal cord as a key pathogenic region in spinocerebellar ataxia type 3
|Frontiers in Cellular Neuroscience|2026|0